OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer

Wen,Kun-Ming; Zhang,Gui-Hai; Li,Jiang; Chen,Zheng-Quan; Cheng,Yi-Lin; Su,Xuan; Zeng,Qing-Liang

doi:10.3892/or.2015.4286

OCT4B1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer

Authors:
- Kun-Ming Wen
- Gui-Hai Zhang
- Jiang Li
- Zheng-Quan Chen
- Yi-Lin Cheng
- Xuan Su
- Qing-Liang Zeng
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, P.R. China, Department of Abdominal Oncology, The Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563000, P.R. China
Published online on: September 17, 2015 https://doi.org/10.3892/or.2015.4286
Pages: 2943-2952

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

OCT4B1, a splice variant of OCT4, is a key regulator in maintaining the properties of pluripotency and self-renewal in embryonic stem (ES) cells. Recent results have shown that OCT4B1 is involved in tumorigenesis. However, the contribution of OCT4B1 in the tumorigenesis and drug resistance of colon cancer remains to be determined. The aim of the present study was to determine whether OCT4B1, which maintains the stemness of ES cells, promoted cell growth by facilitating transition of the cell cycle and reduced apoptosis in colon cancer and drug‑resistant cells using flow cytometry and western blotting. The results showed that, OCT4B1 promoted the growth of colon cancer and drug‑resistant cancer cells by maintaining the activity of ES cells and by facilitating the transition of the cell cycle and reducing apoptosis. Additionally, OCT4B1 was able to reduce sensitivity to oxaliplatin by altering the expression of two important mediators in drug resistance, P-gp and ABCG2 [ATP-binding cassette, sub‑family G (WHITE), member 2]. Furthermore, OCT4B1 enhanced the ability of migration and invasion through alteration of the epithelial-to-mesenchymal transition (EMT) in colon cancer. In conclusion, to the best of our knowledge, the results demonstrated for the first time that OCT4B1 functions as an oncogene in colon cancer and provides the development of novel therapeutic strategies to treat colon cancer, particularly drug resistance.

View Figures

View References

1	Slattery ML and Fitzpatrick FA: Convergence of hormones, inflammation, and energy-related factors: A novel pathway of cancer etiology. Cancer Prev Res (Phila). 2:922–930. 2009. View Article : Google Scholar
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
3	Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
4	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
5	Hofmanová J, Straková N, Vaculová AH, Tylichová Z, Safaříková B, Skender B and Kozubík A: Interaction of dietary fatty acids with tumour necrosis factor family cytokines during colon inflammation and cancer. Mediators Inflamm. 2014:8486322014. View Article : Google Scholar : PubMed/NCBI
6	Chen D, Yu Z, Zhu Z and Lopez CD: The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells. Cancer Res. 66:3485–3494. 2006. View Article : Google Scholar : PubMed/NCBI
7	Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, Schöler H and Smith A: Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 95:379–391. 1998. View Article : Google Scholar : PubMed/NCBI
8	Fankam AG, Kuiate JR and Kuete V: Antibacterial activities of Beilschmiedia obscura and six other Cameroonian medicinal plants against multi-drug resistant Gram-negative phenotypes. BMC Complement Altern Med. 14:2412014. View Article : Google Scholar : PubMed/NCBI
9	Sui H, Liu X, Jin BH, Pan SF, Zhou LH, Yu NA, Wu J, Cai JF, Fan ZZ, Zhu HR, et al: Zuo Jin Wan, a traditional Chinese herbal formula, reverses P-gp-mediated MDR in vitro and in vivo. Evid Based Complement Alternat Med. 2013:9570782013. View Article : Google Scholar : PubMed/NCBI
10	Sui H, Fan ZZ and Li Q: Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 40:426–435. 2012. View Article : Google Scholar : PubMed/NCBI
11	Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ and Andrews PW: OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells. 26:3068–3074. 2008. View Article : Google Scholar : PubMed/NCBI
12	Wang X and Dai J: Concise review: Isoforms of OCT4 contribute to the confusing diversity in stem cell biology. Stem Cells. 28:885–893. 2010.PubMed/NCBI
13	Li R, Liang J, Ni S, Zhou T, Qing X, Li H, He W, Chen J, Li F, Zhuang Q, et al: A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell. 7:51–63. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li Z, Li X, Li C, Su Y, Fang W, Zhong C, Ji W, Zhang Q and Su C: Transcription factor OCT4 promotes cell cycle progression by regulating CCND1 expression in esophageal carcinoma. Cancer Lett. 354:77–86. 2014. View Article : Google Scholar : PubMed/NCBI
15	Asadzadeh J, Asadi MH, Shakhssalim N, Rafiee MR, Kalhor HR, Tavallaei M and Mowla SJ: A plausible anti-apoptotic role of up-regulated OCT4B1 in bladder tumors. Urol J. 9:574–580. 2012.PubMed/NCBI
16	Asadi MH, Mowla SJ, Fathi F, Aleyasin A, Asadzadeh J and Atlasi Y: OCT4B1, a novel spliced variant of OCT4, is highly expressed in gastric cancer and acts as an antiapoptotic factor. Int J Cancer. 128:2645–2652. 2011. View Article : Google Scholar
17	Mirzaei MR, Najafi A, Arababadi MK, Asadi MH and Mowla SJ: Altered expression of apoptotic genes in response to OCT4B1 suppression in human tumor cell lines. Tumour Biol. 35:9999–10009. 2014. View Article : Google Scholar : PubMed/NCBI
18	Valianou M, Cox AM, Pichette B, Hartley S, Paladhi UR and Astrinidis A: Pharmacological inhibition of polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Cell Cycle. 14:399–407. 2015. View Article : Google Scholar : PubMed/NCBI
19	Chen L, Zhang JJ and Huang XY: cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. J Biol Chem. 283:13799–13805. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lee J, Kim HK, Rho JY, Han YM and Kim J: The human OCT-4 isoforms differ in their ability to confer self-renewal. J Biol Chem. 281:33554–33565. 2006. View Article : Google Scholar : PubMed/NCBI
21	Wang X, Zhao Y, Xiao Z, Chen B, Wei Z, Wang B, Zhang J, Han J, Gao Y, Li L, et al: Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. Stem Cells. 27:1265–1275. 2009. View Article : Google Scholar : PubMed/NCBI
22	Pardal R, Clarke MF and Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 3:895–902. 2003. View Article : Google Scholar
23	Al-Hajj M and Clarke MF: Self-renewal and solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
24	Lobo NA, Shimono Y, Qian D and Clarke MF: The biology of cancer stem cells. Annu Rev Cell Dev Biol. 23:675–699. 2007. View Article : Google Scholar : PubMed/NCBI
25	Junker K, Wolf M and Schubert J: Molecular clonal analysis of recurrent bladder cancer. Oncol Rep. 14:319–323. 2005.PubMed/NCBI
26	Engers R: Reproducibility and reliability of tumor grading in urological neoplasms. World J Urol. 25:595–605. 2007. View Article : Google Scholar : PubMed/NCBI
27	Wang XK, To KK, Huang LY, Xu JH, Yang K, Wang F, Huang ZC, Ye S and Fu LW: Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget. 5:11971–11985. 2014. View Article : Google Scholar : PubMed/NCBI
28	Greenberg RM: Schistosome ABC multidrug transporters: From pharmacology to physiology. Int J Parasitol Drugs Drug Resist. 4:301–309. 2014. View Article : Google Scholar : PubMed/NCBI
29	Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2:563–572. 2002. View Article : Google Scholar : PubMed/NCBI
30	Servant G, Weiner OD, Herzmark P, Balla T, Sedat JW and Bourne HR: Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science. 287:1037–1040. 2000. View Article : Google Scholar : PubMed/NCBI
31	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI